Ability to test for Spike Protein and Necleocapsid in NZ Pathology Labs for SARS-COV2

Chris Johnston made this Official Information request to Health New Zealand

The request was partially successful.

From: Chris Johnston

Dear Health New Zealand,

This OIA asks firstly about which labs undertake the tests I am interested in, while the second part focuses (in the event that there are no labs that can do the test) on why this is the case in NZ.

I would ask that you seek clarification on what I mean if it appears that I have mis-used terms because I am not a health professional and the purpose of my query may be easier to communicate by conversation or "consultation" as outlined in the OI Act's clauses.

FIRST PART - availability questions
Do Health New Zealand (HNZ) owned and funded labs have the ability to test for SARS-COV2 Spike Protein and Necleocapsid? That is, if a patient requested a tissue sample be tested for these, do Health New Zealand owned or funded labs acquired the immunohistochemistry technology to do this staining/test?

For context, this pdf provides some background with respect to an autopsy. https://www.skirsch.com/covid/Burkhardt....

Which labs is a patient or specialist able to refer a specimen to? - as opposed to labs that are only available for research purposes and not for "general health" use.

Is HNZ aware of any private labs in NZ offering these tests? Eg do you have a licensing role or use private labs (unfunded and not owned by HNZ) as suppliers?

SECOND PART - if no such tests are available in NZ via HNZ funded or owned labs
If there has been a decision by Health New Zealand to not acquire or use the immunohistochemistry technology for this test, or to not make it available for the public's use, then please provide:
1) an explanation of the rationale in summary form
2) the policy paper(s) that discussed and recommended this approach and
3) any minutes for the meeting that confirmed the decision. This meeting might have occurred at any Auckland labs, the Auckland DHB, MoH, HNZ or cabinet level. I am not interested in other geographic areas for this question, but want to account for the previous health sector structure in my geographic area.

How does HNZ detect conditions/deaths/safety signals that are a result of harms from the SARS-COV2 virus, any treatments or mRNA technology be monitored in New Zealand? Please list the indicators/metrics monitored and provide the policy paper that lists the strategy and the metrics.

In HNZ's policy decisions with respect to SARS-COV2 or the mRNA technology, is an inability to request these tissue tests for Spike Protein or Necleocapsid by clinicians considered an additional barrier to HNZ and/or clinicians:
a) effective measurement and ability to detect any safety signal - eg creating/capturing the raw data?
b) manage any underlying drivers of health and disability via an evidence/data driven approach - i.e. the analytics and decision support that is not possible?

Yours faithfully,
Chris Johnston

Link to this

From: hnzOIA
Health New Zealand

Tēnā koe, 

 

Thank you for contacting Te Whatu Ora, Health NZ. This is an automatic
reply to confirm that we have received your email.  Depending on the
nature of your request you may not receive a response for up to 20 working
days.  We will try to respond to your query as quickly as possible.

s information that is identified to be of general public interest, the
response may also be published on our website. If we e response to your
OIA request, all personal information, including your name and contact
details will be removed.

 

Ngā mihi

 

Te Whatu Ora, Health NZ.

show quoted sections

Link to this

From: hnzOIA
Health New Zealand


Attachment image.jpeg.jpg
4K Download


Tēnā koe Chris,

Thank you for your email of 14 April 2023, asking for the following
information under the Official Information Act 1982 (the Act):

 1. “FIRST PART - availability questions

 1. Do Health New Zealand (HNZ) owned and funded labs have the
ability to test for SARS-COV2 Spike Protein and Necleocapsid?
That is, if a patient requested a tissue sample be tested for
these, do Health New Zealand owned or funded labs acquired the
immunohistochemistry technology to do this staining/test? For
context, this pdf provides some background with respect to an
autopsy. 
[1]https://scanmail.trustwave.com/?c=15517&...

 1. 
 2. Which labs is a patient or specialist able to refer a specimen
to? - as opposed to labs that are only available for research
purposes and not for "general health" use.
 3. Is HNZ aware of any private labs in NZ offering these tests?  Eg
do you have a licensing role or use private labs (unfunded and
not owned by HNZ) as suppliers?

 2. SECOND PART - if no such tests are available in NZ via HNZ funded or
owned labs. If there has been a decision by Health New Zealand to not
acquire or use the immunohistochemistry technology for this test, or
to not make it available for the public's use, then please provide:

 1. an explanation of the rationale in summary form
 2. the policy paper(s) that discussed and recommended this approach
and
 3. any minutes for the meeting that confirmed the decision. This
meeting might have occurred at any Auckland labs, the Auckland
DHB, MoH, HNZ or cabinet level. I am not interested in other
geographic areas for this question, but want to account for the
previous health sector structure in my geographic area.

 3. How does HNZ detect conditions/deaths/safety signals that are a result
of harms from the SARS-COV2 virus, any treatments or mRNA technology
be monitored in New Zealand?  Please list the indicators/metrics
monitored and provide the policy paper that lists the strategy and the
metrics.
 4. In HNZ's policy decisions with respect to SARS-COV2 or the mRNA
technology, is an inability to request these tissue tests for Spike
Protein or Necleocapsid by clinicians considered an additional barrier
to HNZ and/or clinicians:

 1. effective measurement and ability to detect any safety signal -
eg creating/capturing the raw data?
 2. manage any underlying drivers of health and disability via an
evidence/data driven approach - i.e. the analytics and decision
support that is not possible?

 This email is to let you know that Te Whatu Ora needs more time to make a
decision on your request.

The Act requires that we advise you of our decision on your request no
later than 20 working days after the day we received your request.
Unfortunately, it will not be possible to meet that time limit and we are
therefore writing to notify you of an extension of the time to make our
decision, to 13 June 2023.

This extension is required because the consultations necessary to make a
decision on your request are such that a proper response cannot reasonably
be made within the original time limit.

If you have any questions, please contact us at [2][Health New Zealand request email]

If you are not happy with this extension, you have the right to make a
complaint to the Ombudsman. Information about how to do this is available
at www.ombudsman.parliament.nz or by phoning 0800 802 602.

Nāku iti noa, nā

Te Whatu Ora Ministerial Team
 

show quoted sections

References

Visible links
1. https://scanmail.trustwave.com/?c=15517&...
2. mailto:[Health New Zealand request email]

Link to this

From: hnzOIA
Health New Zealand


Attachment image.jpeg.jpg
4K Download

Attachment HNZ00016320 Chris Johnston.pdf
262K Download View as HTML


Kia ora Chris,
 
Thank you for your request for information on 14 April 2023. Please find
attached our response to your request.
 
If you have any questions, please get in touch at
[1][Health New Zealand request email].
 
If you are not happy with this response, you have the right to make a
complaint to the Ombudsman. Information about how to do this is available
at [2]www.ombudsman.parliament.nz or by phoning 0800 802 602.
 
Ngā mihi,
 
Te Whatu Ora Ministerial Team

show quoted sections

References

Visible links
1. mailto:[Health New Zealand request email]
2. file:///tmp/foiextract20230613-36-rllhme#

Link to this

Things to do with this request

Anyone:
Health New Zealand only: